Aurinia Announces Results of the 2021 Annual General Meeting

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general meeting (the “Meeting”) held on June 7, 2021.

Detailed results of the vote by proxy for the election of directors are provided below:

Nominee	Votes For (%)	Votes Withheld (%)
George M. Milne	80.91	19.09
Peter Greenleaf	92.18	7.82
David R.W. Jayne	93.00	7.00
Joseph P. Hagan	87.15	12.85
Daniel G. Billen	95.64	4.36
R. Hector MacKay-Dunn	93.27	6.73
Jill Leversage	95.05	4.95
Timothy P. Walbert	89.56	10.44

In addition, following final tallies of votes, all other matters voted on at the Meeting were also approved. Voting results on all matters voted on at the Meeting will be filed on SEDAR at www.sedar.com and EDGAR at www.edgar.com.

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.